SCHEDULE 13G/A: K2 HealthVentures Equity Trust Discloses 6.9% Stake in TScan Therapeutics Following Debt Conversion
Beneficial Ownership Report
K2 HealthVentures Equity Trust LLC, along with its managing members, has reported a beneficial ownership of 6.9% in TScan Therapeutics, Inc., totaling 3,602,700 shares as of December 31, 2024, primarily due to the conversion of $15 million in term loans into equity.
Summary
- K2 HealthVentures Equity Trust LLC, Parag Shah, and Anup Arora collectively reported beneficial ownership of 3,602,700 shares of TScan Therapeutics, Inc. Voting Common Stock.
- This ownership represents approximately 6.9% of the company's outstanding shares as of December 31, 2024.
- The calculation is based on 49,094,006 shares outstanding as of November 7, 2024, plus an additional 3,134,796 shares issued to K2HV Equity on November 20, 2024.
- The additional shares resulted from the conversion of $15 million principal amount of term loans under a Loan and Security Agreement dated September 9, 2022.
- The reporting persons share both voting and dispositive power over all 3,602,700 shares.
- The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer, except for potential activities related to a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While the debt conversion causes dilution, it also strengthens the balance sheet by reducing debt and shows continued commitment from a significant investor. The filing itself is a routine disclosure of a previously reported event.
Positives
- A significant institutional investor, K2 HealthVentures Equity Trust, holds a substantial stake, potentially indicating confidence in TScan Therapeutics.
- The conversion of $15 million in debt to equity by K2HV Equity strengthens the company's balance sheet by reducing its debt obligations.
Negatives
- The conversion of debt to equity, while reducing debt, results in dilution for existing shareholders due to the issuance of 3,134,796 new shares.
Risks
- Dilution of existing shareholders' ownership percentage due to the issuance of new shares from the debt conversion.
Future Outlook
This Schedule 13G filing is a statement of beneficial ownership and does not contain forward-looking statements or guidance regarding TScan Therapeutics, Inc.'s future operations or financial performance.
Management Comments
- The filing includes a certification from the reporting persons stating that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing indicates a significant investment by a health ventures equity trust in a biotechnology company, which is common in the life sciences sector where specialized funds provide capital in exchange for equity, often through convertible debt instruments. The conversion of debt to equity is a typical mechanism for such investors to realize their investment or adjust their capital structure within a portfolio company.
Related Party Transactions
- The filing details a transaction where K2 HealthVentures Equity Trust LLC, a reporting person, converted $15 million in term loans into equity of TScan Therapeutics, Inc., which is a related party transaction given their significant investment and prior loan agreement.
Stakeholder Impact
- Shareholders: Experience dilution due to the issuance of new shares, but the company's balance sheet is strengthened by debt reduction.
- Creditors: K2HV Equity, as a former creditor (for the converted loan), has transitioned to an equity holder, reducing the company's debt obligations.
Next Steps
- The document does not specify any future actions, events, or milestones for TScan Therapeutics, Inc. or the reporting persons, beyond the ongoing requirement to update beneficial ownership if changes occur.
Key Dates
| Date | Description |
|---|---|
| 2022-09-09 | Date of the Loan and Security Agreement between TScan Therapeutics, Inc. and K2HV Equity. |
| 2024-11-07 | Date as of which 49,094,006 shares of Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 2024-11-12 | Date the Issuer's quarterly report on Form 10-Q was filed with the SEC. |
| 2024-11-20 | Date 3,134,796 shares of Common Stock were issued to K2HV Equity as a result of term loan conversion. |
| 2024-12-26 | Date the Issuer's prospectus supplement on Form 424B5 was filed with the SEC, reporting the share issuance. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for ownership calculation). |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
TScan Therapeutics, K2 HealthVentures Equity Trust, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, Debt Conversion, Biotechnology, Pharmaceuticals, Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.